LEVER Trial: Levonorgestrel Intrauterine Device Alone or in Combination with an mTORC1 Inhibitor to Overcome Progesterone Resistance in Atypical Hyperplasia or Stage Ia Grade 1 Endometrioid Endometrial Cancer

Authors

Ernesto Saul Flores Barrera, The University of Texas MD Anderson Cancer Center
Tina Alvarado, The University of Texas MD Anderson Cancer Center
Gaby Granda, The University of Texas MD Anderson Cancer Center
Sara Hull, The University of Texas MD Anderson Cancer Center
Larissa A. Meyer, The University of Texas MD Anderson Cancer Center
Melinda Yates, The University of Texas MD Anderson Cancer Center
Shannon N. Westin, The University of Texas MD Anderson Cancer Center

Files

Publisher

The University of Texas MD Anderson Cancer Center

City

Houston

Keywords

endometrial cancer, everolimus, progesterone, levonorgestrel

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Program Affiliation

Partnership for Careers in Cancer Science and Medicine

Recommended Citation

Flores Barrera, Ernesto Saul; Alvarado, Tina; Granda, Gaby; Hull, Sara; Meyer, Larissa A.; Yates, Melinda; and Westin, Shannon N., "LEVER Trial: Levonorgestrel Intrauterine Device Alone or in Combination with an mTORC1 Inhibitor to Overcome Progesterone Resistance in Atypical Hyperplasia or Stage Ia Grade 1 Endometrioid Endometrial Cancer" (2021). Summer Experience 2021. 79.
https://openworks.mdanderson.org/sumexp21/79